Skip to main navigation
Skip to main content
KENTUCKY
Board of Pharmacy
Licensure Gateway Portal
MENU
Board Information
Overview
Board Members
Board Staff
Board Meetings
Board Committees
Facilities
Overview
Pharmacy Permits
Manufacturers
Wholesalers
Third Party Logistics Providers
Outsourcer Facilities
Legend Drug Repository Program
Professionals
Overview
Pharmacist Information
Pharmacist Interns
Pharmacy Technicians
KY Professionals Recovery Network
Continuing Education
KASPER Information
Resource Documents
Statutes and Regulations
Frequently Asked Questions
KBML Board Actions
Board Authorized Protocols
Additional Resources
Grievance Process
Newsletter Archive
Inspector Regions
Contact Us
Data Rosters
Left Nav Content
Home
/
Important Updates
Important Updates
Updated 12/12/2024
Main Content
NABP National News and Resources
National News
Important Updates
Kentucky Board of Pharmacy August 29, 2024 Press Release
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain
Fighting Fake Medicines Sold Online Requires Commitment to Cautioning Patients
NASCSA News - Announcing Free CE on Prescription Monitoring Programs Available
September 29, 2023 Important Updates from the Kentucky Board of Pharmacy
DSCSA compliance policies establish 1-year stabilization period for implementing electronic systems
Reporting Theft or Significant Loss of Controlled Substances
Accidental Ingestion Information
Tianeptine Now a Schedule I Controlled Substance in Kentucky
Pharmacist CE Requirement 2023-2028: 1 Contact Hour on Opioid Epidemic or Opioid Use Disorder Required Each Year.
USP Revisions 797 & 795: Public comment period now open for draft proposal of 201 KAR 2:076 compounding regulation.
Health Alert: Counterfeit Pharmaceuticals (March 17, 2023)
Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act
PCSC Warns of Additional Product Ordering and Recall Fraud Incidents
Appeals Panel Decisions on USP Compounding Standards
Important changes regarding butalbital containing products
DEA Rescheduling of Hydrocodone Combination Products - Impact on Kentucky Prescribers
Pharmaceutical Controlled Substance Disposal General Public Fact Sheet
Pharmaceutical Controlled Substance Disposal Long Term Care Facility Fact Sheet
Pharmaceutical Controlled Substance Disposal Registrant Fact Sheet
December 22, 2014 Informational Bulletin
Ebola Guidelines
902 KAR 2_020. Reportable disease surveillance (Amended Regulation - TB Reporting)
Synthetic Cannabinoids April 2015
Restrictions on possession of dextromethorphan and sale of products containing dextromethorphan
Gabapentin - Schedule V Controlled Substance
Important Updates